Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Added few more shares.....
this baby is on fire and chieeeeppppppppppppppp!
Integrated BioPharma Reports Results for its Quarter Ended September 30, 2019
Press Release | 11/13/2019
HILLSIDE, NJ / ACCESSWIRE / November 13, 2019 / Integrated BioPharma, Inc. (OTC BB:INBP) (the "Company") reports it financial results for the quarter ended September 30, 2019.
Revenue for the quarter ended September 30, 2019 was $11.4 million compared to $10.3 million for the quarter ended September 30, 2018, an increase of $1.1 million or 10.7%. The Company had operating income for the quarter ended September 30, 2019 of $0.5 million compared to operating income of $0.4 million for the quarter ended September 30, 2018.
For the quarter ended September 30, 2019, the Company had net income and diluted net income of $0.3 million or $0.01 per share of common stock, compared with net income and diluted net income of $0.2 million or $0.01 per share of common stock for the quarter ended September 30, 2018.
"We are excited to report that our revenue increased by approximately 11% in the quarter ended September 30, 2019 and that our revenue from our two significant customers in our Contract Manufacturing Segment remained consistent; representing approximately 91% and 89% of total revenue in the quarters ended September 30, 2019 and 2018, respectively," said Riva Sheppard, Co-Chief Executive Officer of the Company.
A summary of our financial results for the three months ended September 30, 2019 follows:
INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except share and per share amounts)
(unaudited)
Three Months Ended
September 30,
2019 2018
Total revenue
$ 11,406 $ 10,304
Cost of sales
10,007 9,085
Gross profit
1,399 1,219
Selling and administrative expenses
923 814
Operating income
476 405
Other expense, net (1)
(127 ) (191 )
Income before income taxes
349 214
Income tax expense, net
37 55
Net income
$ 312 $ 159
Net income per common share:
Basic
$ 0.01 $ 0.01
Diluted
$ 0.01 $ 0.01
Weighted average common shares outstanding:
Basic
29,565,943 27,218,786
Diluted
30,724,633 27,963,604
(1) Includes interest expense of $124 and $200, respectively.
SOURCE: Integrated BioPharma, Inc.
View source version on accesswire.com:
https://www.accesswire.com/566451/Integrated-BioPharma-Reports-Results-for-its-Quarter-Ended-September-30-2019
I'm surprised there isn't more love here. I saw Q3 financials and they look pretty good.
eps=3c.....
or 12c x 5(pe) = 60c stock in the making.wooowwwww.
Not bad....
Revenue up 11%
eps .008c or 3.2c annualized
inventory is up $2.0 million,must expect $12+ million shipment next few quarters.
Yes,for q2 which ended on 12/31/18......
ER due out most likely today.This company has many moving parts,I hope $500k operating income stays up,generating enough cash and lower their debt level due in 2020.Once inbp got its act together,top line of $10+ million/q can do a lot of damage(in a positive way).
Is this a prediction for the 12/18 Q?
This ER numbers........
rev 11.4 million
cost 10.0 million(88%)
sg&a 0.85 million(7%)
net income 0.28 million(2%) or 1c
forward pe@13c:
13c/1c*4=3.3
Buy.....
q4(6/30/18):
revenue up 12%
net income $818k w/change of derivative&others $461k(benefit).
or
this dog is getting rid of its flee,1 or 2 more q to go,before complete eradication.Wooowwwww.
10Q pending.......
This dog with flee is on the move.A good q coming??
$5.3 million of convertible debt to equity @65c........
With current quote of the stock at 16c,the greatest thing since the sliced of bread just occured,a gift to the shareholders/company.Nothing can be better than this event.Wooowwwwww.
Bottom line to the capital structure:
$4.0 million net debt reduction,at no dilution to its shareholders.
Saving of $318k of interest expense annually.
What a week INBP & IBIO
I smell some HUGE gains here folks
Oh they will :), very interesting week coming. Given how low the float is here, we may see some crazy runs here
***MARK IT***
NEXT EBOLA RUNNER...
IF YOU'RE NOT LOADING, WE ARE...TIC...TOC...TIC...TOC...TIC...TOC...
Surprised more people haven't caught on to this yet ;]
$INBP
INBP-our hidden under the radar gem holding about 1.7 million shares of IBIO woweeee lol. This is going to get very interesting, with less the a million float who knows how high this can reach here. It's IBIO investment alone is about 5.5 million, what's to stop IBIO from surging up much more ahead if it's recent developments.
Things are going to get very interesting, too bad we're so under the radar, I'm sure that'll change :)
Monster is an understatement, market cap is so low and discounted and the float here is only like 1 million
It's crazy to see still at these levels, people haven't the slightest idea
People starting to put 2&2 together I see... Nice!
This will be a monster runner mark it!
Got me a starter position today
I thought you knew for some reason lol!
NOW YA TELL ME!!! HAHAA NICE FIND
INBP valuation is going through the roof. 21 mill OS and 70% owned by insiders. They own 1.2 million shares of IBIO now valued at almost 3 million dollars.
The share price will keep rising with Ibio's advancement.
Whats your opinion on this chart here? Been following it and trying to see where this is going. Newbie here
LOL... Tell my wife that plzzzzzz
LMAO! At least, he's good at something...
Nah just a pumper "LOL"
You know him too??? They say he's very good...
Heard_they_have_an advisor named smitter or something like that...Lol...
Make you go hmmmmmmmmmmm
Yep, and they prob have some insider knowledge of what is going on over at IBIO.
I'm sure they know when's the best time to sell some of their IBIO shares...
What will be interesting also is, what will they do with all that money>>>>
They own 1.2 mill IBIO. They better hold it. IBIO gonna be $10+ prob less than a few weeks. This company is going to be cash heavy!
The higher IBIO goes the more Value this gets and exposure.
.30 next .38-.42
Here we go, watch volume this moves like crazy could see .50 today plus
Investment in iBio, Inc. The Company accounts for its investment in iBio, Inc. (“iBio”) common stock on the cost basis as it retained approximately 6% of its interest in iBio (1,266,706 common shares) (the “iBio Stock”) at the time of the spin-off of this subsidiary in August 2008. The Company reviews its investment in iBio for impairment and records a loss when there is deemed to be an impairment of the investment. There were impairment charges of $152 and $139 recorded in the fiscal years ended June 30, 2014 and 2013, respectively. The market value of the iBio Stock as of June 30, 2014, was approximately $0.5 million. Pursuant to the Company’s Loan Agreement with PNC Bank, National Association (“PNC”), the Company is required to sell the iBio Stock when the trading price of the iBio Stock is less than $0.88 per share for a period of fifteen (15) consecutive trading days on the applicable exchange and utilize all proceeds from such sale to prepay the outstanding principal of the term loan outstanding under the Loan Agreement at such time. In the fiscal years ended June 30, 2014 and 2013, the trading price of the iBio Stock was less than $0.88 for a period of fifteen (15) consecutive trading days. (See Note 6. Senior Credit Facility, Subordinated Convertible Note Payable, net - CD Financial, LLC and other Long Term Debt). As of September 8, 2014, the Company has not sold any shares of the iBio Stock.
Followers
|
18
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
452
|
Created
|
09/09/07
|
Type
|
Free
|
Moderators |
AgroLabs, Inc. manufactures and markets healthful nutritional products under the following brands: Naturally Noni, Naturally Pomegranate, Naturally Aloe, andNaturally Mangosteen. These products are distributed nationwide through major mass market, grocery, drug and vitamin retailers. |
http://www.AgroLabs.com |
| ||||||||||||||||||||||||||||||||||||
|
|
Established in 1922, Manhattan Drug Company provides vitamins and nutritional formulations to customer specifications. | ||||||||||||||
|
|
Gerald Kay |
Chairman of the Board, CEO, and Shareholder. E. Gerald Kay has served as Chairman of the Board and President of the Company and its predecessor since 1980. He was president until May 1999. |
Dina L. Masi |
Chief Financial Officer and Senior Vice President. Ms. Masi most recently operated a financial services consulting firm providing accounting and financial services to small business owners. She also served as a consultant to SEC registrants. Prior to that, she served as the Chief Financial Officer of a mortgage finance company and a Senior Vice President and Management Information Officer of a financial consulting services company. Before that, she served as the Chief Financial Officer of The Aegis Consumer Funding Group, Inc., a publicly traded consumer finance company specializing in automobile receivables. Ms. Masi began her career as an auditor with BDO Seidman, LLP. |
Riva Sheppard |
Vice President, Sales and Manufacturing. Riva Kay Sheppard has served as Vice President and Director of the Company since May 1991. Prior to joining the Company in 1991, she was with United Jersey Bank. |
Christina Kay |
Vice President, Logistics. Christina Kay served as Vice President and Director of the Company since December 1994. Previously she was with the New York law firm of Squadron, Ellenoff, Plesant, Sheinfeld & Sorkin. |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |